Current Report Filing (8-k)
09 January 2020 - 8:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
January 8, 2020
Date of report (Date of earliest event reported)
Agile Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-36464
|
23-2936302
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
101 Poor Farm Road
Princeton, New Jersey
(Address of principal executive offices)
|
08540
(Zip Code)
|
|
|
|
|
Registrant's telephone number, including
area code (609) 683-1880
(Former name or former address, if changed
since last report)
|
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425).
¨ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12).
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading symbol
|
Name of exchange on which registered
|
Common stock, par value $0.0001 per share
|
AGRX
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition.
As discussed below, in connection with
its participation in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California beginning on January
13th, 2020, Agile Therapeutics, Inc. (the “Company”) updated its corporate presentation to include disclosure that
the Company had an estimated $34.5 million of cash and cash equivalents as of December 31, 2019, which includes the proceeds of
approximately $19.3 million, net of expenses, from the sale of approximately 10.4 million shares of the Company’s common
stock, par value $0.0001 per share (“Placement Shares”), representing the full amount of shares authorized for sale
by the Company in the at-the-market offering conducted pursuant to the Common Stock Sales Agreement dated November 8, 2019 (the
“Sales Agreement”) with H.C. Wainwright & Co., LLC. The issuance and sale of the Placement Shares by the Company
under the Sales Agreement was made pursuant to a prospectus supplement to the Company’s registration statement on Form S-3,
originally filed with the Securities and Exchange Commission (the “SEC”) on November 2, 2018, and declared effective
by the SEC on November 14, 2018. The Company believes its estimated cash and cash equivalents as of December 31, 2019 will be sufficient
to meet its projected operating requirements into September 2020.
Because the Company’s financial statements for the year
ended December 31, 2019 have not yet been finalized or audited, the preliminary statement of the Company’s cash and cash
equivalents as of December 31, 2019 in this Item 2.02 is subject to change, and the Company’s actual cash and cash equivalents
as of the end of this period may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance
on this preliminary estimate.
Item 8.01. Other Events.
Beginning on January 13, 2019, the Company
will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The Company has
updated its corporate presentation that it intends to use in connection with its presentation at the Biotech Showcase 2020 on Tuesday
January 14, 2020 at 10:00 a.m. Pacific Time, at the J.P. Morgan 2020 Healthcare Conference on Thursday, January 16, 2020 at 10:30
a.m. Pacific Time, and in meetings with investors. The updates primarily involve disclosure regarding the Company’s cash
and cash equivalents as of December 31, 2019 as well as the Company’s plans for commercialization upon the approval of AG200
(Twirla®).
A copy of the Company’s corporate presentation is attached
hereto as Exhibit 99.1 and is hereby incorporated by reference herein.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Agile Therapeutics, Inc.
|
|
|
Dated: January 8, 2020
|
By:
|
/s/ Alfred Altomari
|
|
Name: Alfred Altomari
|
|
Title: Chairman and Chief Executive Officer
|
Agile Therapeutics (QB) (USOTC:AGRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agile Therapeutics (QB) (USOTC:AGRX)
Historical Stock Chart
From Jul 2023 to Jul 2024